Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Radioimmunotherapy of human tumours.

Larson SM, Carrasquillo JA, Cheung NK, Press OW.

Nat Rev Cancer. 2015 Jun;15(6):347-60. doi: 10.1038/nrc3925. Review. Erratum in: Nat Rev Cancer. 2015 Aug;15(8):509.

2.

α-Radioimmunotherapy with ²¹³Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma.

Teiluf K, Seidl C, Blechert B, Gaertner FC, Gilbertz KP, Fernandez V, Bassermann F, Endell J, Boxhammer R, Leclair S, Vallon M, Aichler M, Feuchtinger A, Bruchertseifer F, Morgenstern A, Essler M.

Oncotarget. 2015 Mar 10;6(7):4692-703.

3.

A hybrid protein-polymer nanoworm potentiates apoptosis better than a monoclonal antibody.

Aluri SR, Shi P, Gustafson JA, Wang W, Lin YA, Cui H, Liu S, Conti PS, Li Z, Hu P, Epstein AL, MacKay JA.

ACS Nano. 2014 Mar 25;8(3):2064-76. doi: 10.1021/nn403973g. Epub 2014 Feb 14.

4.

Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab.

Heyerdahl H, Abbas N, Brevik EM, Mollatt C, Dahle J.

PLoS One. 2012;7(8):e42345. doi: 10.1371/journal.pone.0042345. Epub 2012 Aug 3.

5.

Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab.

Abbas N, Heyerdahl H, Bruland OS, Borrebæk J, Nesland J, Dahle J.

EJNMMI Res. 2011 Aug 24;1(1):18. doi: 10.1186/2191-219X-1-18.

6.

Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model.

Pagel JM, Kenoyer AL, Bäck T, Hamlin DK, Wilbur DS, Fisher DR, Park SI, Frayo S, Axtman A, Orgun N, Orozco J, Shenoi J, Lin Y, Gopal AK, Green DJ, Appelbaum FR, Press OW.

Blood. 2011 Jul 21;118(3):703-11. doi: 10.1182/blood-2011-04-347039. Epub 2011 May 25.

7.

MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy.

Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, Brill AB, Song H, Howell RW, Akabani G; SNM MIRD Committee, Bolch WE, Brill AB, Fisher DR, Howell RW, Meredith RF, Sgouros G, Wessels BW, Zanzonico PB.

J Nucl Med. 2010 Feb;51(2):311-28. doi: 10.2967/jnumed.108.058651. Epub 2010 Jan 15.

8.

Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y.

Song H, Hobbs RF, Vajravelu R, Huso DL, Esaias C, Apostolidis C, Morgenstern A, Sgouros G.

Cancer Res. 2009 Dec 1;69(23):8941-8. doi: 10.1158/0008-5472.CAN-09-1828. Epub 2009 Nov 17.

9.

Imaging virus-associated cancer.

Fu DX, Foss CA, Nimmagadda S, Ambinder RF, Pomper MG.

Curr Pharm Des. 2008;14(28):3048-65. Review.

10.

213Bi (alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model.

Song H, Shahverdi K, Huso DL, Esaias C, Fox J, Liedy A, Zhang Z, Reilly RT, Apostolidis C, Morgenstern A, Sgouros G.

Cancer Res. 2008 May 15;68(10):3873-80. doi: 10.1158/0008-5472.CAN-07-6308. Erratum in: Cancer Res. 2008 Jun 15;68(12):4958. Liedy, Allison [corrected to Liedy, Alyson].

Supplemental Content

Support Center